135 related articles for article (PubMed ID: 37160241)
1. Optimal dosing regimen of biapenem based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation in patients with febrile neutropenia and haematological malignancies.
Rao Q; Yang Y; Wang S; Zhu H; Jin L; Zhang J; Liu M
Int J Antimicrob Agents; 2023 Jul; 62(1):106841. PubMed ID: 37160241
[TBL] [Abstract][Full Text] [Related]
2. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
[TBL] [Abstract][Full Text] [Related]
3. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
[TBL] [Abstract][Full Text] [Related]
5. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
[TBL] [Abstract][Full Text] [Related]
6. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
Nomura K; Morikawa N; Ikawa K; Ikeda K; Fujimoto Y; Shimizu D; Taniguchi K; Shimura K; Kanbayashi Y; Komori T; Matsumoto Y; Fujita N; Shimazaki C; Taniwaki M
J Antimicrob Chemother; 2008 Apr; 61(4):892-900. PubMed ID: 18276604
[TBL] [Abstract][Full Text] [Related]
7. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis.
Ohata Y; Tomita Y; Nakayama M; Tamura K; Tanigawara Y
J Infect Chemother; 2011 Dec; 17(6):831-41. PubMed ID: 21773752
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic profiling of four antimicrobials against Acinetobacter baumannii infection.
Zhu W; Chu Y; Zhang J; Xian W; Xu X; Liu H
Microb Pathog; 2020 Jan; 138():103809. PubMed ID: 31634531
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation.
Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
Int J Antimicrob Agents; 2008 Oct; 32(4):339-43. PubMed ID: 18602798
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and
Cojutti PG; Candoni A; Lazzarotto D; Filì C; Zannier M; Fanin R; Pea F
Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32825109
[TBL] [Abstract][Full Text] [Related]
13. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
15. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
[TBL] [Abstract][Full Text] [Related]
16. Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies.
Sime FB; Roberts MS; Tiong IS; Gardner JH; Lehman S; Peake SL; Hahn U; Warner MS; Roberts JA
Antimicrob Agents Chemother; 2015 Sep; 59(9):5463-9. PubMed ID: 26124158
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics, dosing optimization and clinical outcomes of biapenem in patients with sepsis.
Chen D; Wu X; Zhang H; Yao H; Jin L; Luo X; Liu J; Wu Z; Li Y; Xu W; Ge W; Chen X; Zhu H
Front Pharmacol; 2024; 15():1388150. PubMed ID: 38799155
[No Abstract] [Full Text] [Related]
18. Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
Lepe JA; García-Cabrera E; Gil-Navarro MV; Aznar J
Rev Esp Quimioter; 2012 Jun; 25(2):134-8. PubMed ID: 22707102
[TBL] [Abstract][Full Text] [Related]
19. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia.
Jaruratanasirikul S; Wongpoowarak W; Jullangkoon M; Samaeng M
J Pharmacol Sci; 2015 Feb; 127(2):164-9. PubMed ID: 25727953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
